Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome

Yokota, Takashi; Kinugawa, Shintaro; Hirabayashi, Kagami; Suga, Tadashi; Takada, Shingo; Omokawa, Masashi; Kadoguchi, Tomoyasu; Takahashi, Masashige; Fukushima, Arata; Matsushima, Shouji; Yamato, Mayumi; Okita, Koichi; Tsutsui, Hiroyuki

Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome

Yokota, Takashi; Kinugawa, Shintaro; Hirabayashi, Kagami et al.

Journal of Diabetes Investigation, 2017, 8(4), 535-541

Permalink : https://hdl.handle.net/2115/67069

このアイテムのアクセス数:1,000件（2026-08-11 15:15 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Yokota_et_al-2017-Journal_of_Diabetes_Investigation	pdf	365 KB	712

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/67069
タイトル	Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
著者	Yokota, Takashi ; Kinugawa, Shintaro ; Hirabayashi, Kagami ; Suga, Tadashi ; Takada, Shingo ; Omokawa, Masashi ; Kadoguchi, Tomoyasu ; Takahashi, Masashige ; Fukushima, Arata ; Matsushima, Shouji ; Yamato, Mayumi ; Okita, Koichi ; Tsutsui, Hiroyuki
e-Rad_Researcher 90374321 著者名 Yokota, Takashi
e-Rad_Researcher 60399871 著者名 Kinugawa, Shintaro
著者名 Hirabayashi, Kagami
e-Rad_Researcher 30708673 著者名 Suga, Tadashi
e-Rad_Researcher 60722329 著者名 Takada, Shingo
著者名 Omokawa, Masashi
著者名 Kadoguchi, Tomoyasu
著者名 Takahashi, Masashige
e-Rad_Researcher 40706553 著者名 Fukushima, Arata
著者名 Matsushima, Shouji
e-Rad_Researcher 30380695 著者名 Yamato, Mayumi
e-Rad_Researcher 80382539 著者名 Okita, Koichi
e-Rad_Researcher 70264017 著者名 Tsutsui, Hiroyuki
言語	英語
キーワード	Clinical
	Metabolic syndrome
	Treatment drug
発行日	2017-07
出版者	John Wiley & Sons
収録物名	Journal of Diabetes Investigation
巻(号)	8(4)
ページ	535-541
抄録	Aims/Introduction: Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. Materials and Methods: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole-body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high-energy phosphates in the calf muscle during plantar-flexion exercise were measured using 1proton- and 31phosphorus magnetic resonance spectroscopy, respectively. Results: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post- treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post-treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high-energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. Conclusions: Pioglitazone significantly improved the MetS patients' whole-body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole-body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1124
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.12606